Prima BioMed Revenue 2010-2021 | IMMP
Prima BioMed revenue from 2010 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Prima BioMed Annual Revenue
(Millions of US $) |
| 2021 |
$3 |
| 2020 |
$11 |
| 2019 |
$5 |
| 2018 |
$6 |
| 2017 |
$3 |
| 2016 |
$1 |
| 2015 |
$2 |
| 2014 |
$3 |
| 2013 |
$3 |
| 2012 |
$0 |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Prima BioMed Quarterly Revenue
(Millions of US $) |
| 2021-12-31 |
|
| 2017-03-31 |
$1 |
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-06-30 |
|
| 2010-06-30 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.236B |
$0.003B |
|
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
|
